Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions: Metformin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more

Conditions: Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions: Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 662
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more

Conditions: Overweight, Obesity
Interventions: VI-0521, Placebo, Alcohol, alcohol placebo; Drug · Other
Lead sponsor: VIVUS LLC; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cushing's Disease
Interventions: osilodrostat, osilodrostat Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 37
States / cities: Hoover, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: COVID-19, Olfactory Disorder, Parosmia
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer
Interventions: 5-FU, FOLFOX regimen, Placebo, bevacizumab [Avastin], leucovorin, onartuzumab [MetMAb]; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 23
States / cities: San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more

Conditions: HIV-1 Infection
Interventions: DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 74
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more

Conditions: Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions: N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection; Other · Procedure · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 30 Days to 100 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB078, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Premenstrual Dysphoric Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Richmond, Virginia

Conditions: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, Topical Vehicle Gel; Drug
Lead sponsor: Pelage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more

Conditions: Healthy Participants
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 23
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more

Conditions: Cocaine Use
Interventions: l-THP (l-tetrahydropalmatine), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Prostate Cancer
Interventions: Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT); Other · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depression
Interventions: venlafaxine (Effexor), placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Lisdexamfetamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Trigeminal Neuropathic Pain
Interventions: PET Scans, transcranial direct current stimulation (tDCS), MRI, sham tDCS (prior to real tDCS); Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions: Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Investigative Site, New Jersey

Conditions: Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions: Oceanix, Resistance Training; Dietary Supplement · Other
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Opioid Use Disorder
Interventions: Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg; Drug
Lead sponsor: Yasmin Hurd; Other
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Search by objective public record fields.

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Beta-blocker Administration for Cardiomyocyte Division

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Physiologic Monitoring of Antidepressant Response

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

The Long-term Effects of Oceanix™ on Resistance Training Adaptations

Cannabidiol in the Treatment of Opioid Use Disorder

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)